Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.
作者信息
Petrof Gabriela, Lwin Su M, Martinez-Queipo Magdalena, Abdul-Wahab Alya, Tso Simon, Mellerio Jemima E, Slaper-Cortenbach Ineke, Boelens Jaap J, Tolar Jakub, Veys Paul, Ofuya Mercy, Peacock Janet L, Martinez Anna E, McGrath John A
机构信息
St John's Institute of Dermatology, King's College London (Guy's Campus), London, UK.
St John's Institute of Dermatology, King's College London (Guy's Campus), London, UK.
出版信息
J Invest Dermatol. 2015 Sep;135(9):2319-2321. doi: 10.1038/jid.2015.158. Epub 2015 Apr 23.
Abstract
摘要
相似文献
1
Potential of Systemic Allogeneic Mesenchymal Stromal Cell Therapy for Children with Recessive Dystrophic Epidermolysis Bullosa.
J Invest Dermatol. 2015 Sep;135(9):2319-2321. doi: 10.1038/jid.2015.158. Epub 2015 Apr 23.
2
Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa.
J Am Acad Dermatol. 2020 Aug;83(2):447-454. doi: 10.1016/j.jaad.2019.11.038. Epub 2019 Nov 28.
3
Toxic Epidermal Necrolysis in Recessive Dystrophic Epidermolysis Bullosa following Bone Marrow Transplantation.
J Pediatr. 2016 Jun;173:242-4. doi: 10.1016/j.jpeds.2016.02.037. Epub 2016 Mar 11.
4
Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa.
J Pediatr. 2015 Sep;167(3):765-9.e1. doi: 10.1016/j.jpeds.2015.05.051. Epub 2015 Jul 3.
5
Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa.
Stem Cell Res Ther. 2014 Nov 6;5(6):121. doi: 10.1186/scrt511.
6
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
J Am Acad Dermatol. 2013 Dec;69(6):898-908.e7. doi: 10.1016/j.jaad.2013.08.014. Epub 2013 Sep 24.
7
Inpatient management of children with recessive dystrophic epidermolysis bullosa: A review.
Pediatr Dermatol. 2017 Nov;34(6):647-655. doi: 10.1111/pde.13276. Epub 2017 Sep 25.
8
Japanese guidelines for diagnosis and treatment of junctional and dystrophic epidermolysis bullosa.
Arch Dermatol Res. 2003 Apr;295 Suppl 1:S24-8. doi: 10.1007/s00403-002-0379-y. Epub 2003 Mar 11.
9
Recessive Dystrophic Epidermolysis Bullosa: Advances in the Laboratory Leading to New Therapies.
J Invest Dermatol. 2015 Jul;135(7):1705-1707. doi: 10.1038/jid.2015.149.
10
Dystrophic epidermolysis bullosa.
J Perinatol. 2004 Jan;24(1):41-7. doi: 10.1038/sj.jp.7211019.
引用本文的文献
1
Mesenchymal intravenous stromal cell infusions in children with recessive dystrophic epidermolysis bullosa: MissionEB protocol for a randomised, double-blinded, placebo-controlled, two-centre, crossover trial with an internal phase I dose de-escalation phase and open-label extension.
BMJ Open. 2025 May 21;15(5):e089857. doi: 10.1136/bmjopen-2024-089857.
2
Evaluation of safety and efficacy of multiple intravenous and intraosseous doses of foetal liver-derived mesenchymal stem cells in children with severe osteogenesis imperfecta : the BOOST2B clinical trial protocol.
Bone Jt Open. 2025 Mar 24;6(3):361-372. doi: 10.1302/2633-1462.63.BJO-2024-0115.R1.
3
Progress in skin gene therapy: From the inside and out.
Mol Ther. 2025 May 7;33(5):2065-2081. doi: 10.1016/j.ymthe.2025.03.017. Epub 2025 Mar 12.
4
Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial.
EClinicalMedicine. 2024 Oct 30;77:102900. doi: 10.1016/j.eclinm.2024.102900. eCollection 2024 Nov.
5
Current Status of Biomedical Products for Gene and Cell Therapy of Recessive Dystrophic Epidermolysis Bullosa.
Int J Mol Sci. 2024 Sep 24;25(19):10270. doi: 10.3390/ijms251910270.
6
Revolutionizing dermatology: harnessing mesenchymal stem/stromal cells and exosomes in 3D platform for skin regeneration.
Arch Dermatol Res. 2024 May 25;316(6):242. doi: 10.1007/s00403-024-03055-4.
7
Twin Prime Editing Mediated Exon Skipping/Reinsertion for Restored Collagen VII Expression in Recessive Dystrophic Epidermolysis Bullosa.
J Invest Dermatol. 2024 Dec;144(12):2764-2777.e9. doi: 10.1016/j.jid.2024.04.013. Epub 2024 May 17.
8
Donor Muse Cell Treatment Without HLA-Matching Tests and Immunosuppressant Treatment.
Stem Cells Transl Med. 2024 Jun 14;13(6):532-545. doi: 10.1093/stcltm/szae018.
9
Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa.
J Appl Genet. 2024 Dec;65(4):705-726. doi: 10.1007/s13353-024-00839-2. Epub 2024 Mar 9.
10
Advances in Treatments for Epidermolysis Bullosa (EB): Emphasis on Stem Cell-Based Therapy.
Stem Cell Rev Rep. 2024 Jul;20(5):1200-1212. doi: 10.1007/s12015-024-10697-4. Epub 2024 Mar 2.
本文引用的文献
1
Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification.
J Am Acad Dermatol. 2014 Jun;70(6):1103-26. doi: 10.1016/j.jaad.2014.01.903. Epub 2014 Mar 29.
2
Evaluation of wound care options in patients with recessive dystrophic epidermolysis bullosa: a costly necessity.
Pediatr Dermatol. 2014 Jan-Feb;31(1):33-7. doi: 10.1111/pde.12243. Epub 2013 Nov 14.
3
A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.
J Am Acad Dermatol. 2013 Dec;69(6):898-908.e7. doi: 10.1016/j.jaad.2013.08.014. Epub 2013 Sep 24.
4
Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial.
Br J Dermatol. 2013 Nov;169(5):1025-33. doi: 10.1111/bjd.12599.
5
Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.
N Engl J Med. 2010 Aug 12;363(7):629-39. doi: 10.1056/NEJMoa0910501.
6
Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa.
Cytotherapy. 2010 May;12(3):429-31. doi: 10.3109/14653241003587637.
7
Stem cell paracrine actions and tissue regeneration.
Regen Med. 2010 Jan;5(1):121-43. doi: 10.2217/rme.09.74.
8
Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs.
J Am Acad Dermatol. 2009 Sep;61(3):387-402; quiz 403-4. doi: 10.1016/j.jaad.2009.03.053.
9
Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing.
PLoS One. 2008 Apr 2;3(4):e1886. doi: 10.1371/journal.pone.0001886.
10
Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair--current views.
Stem Cells. 2007 Nov;25(11):2896-902. doi: 10.1634/stemcells.2007-0637. Epub 2007 Sep 27.
Zotero 插件